Yabao, Salus announce generics partnership

BEIJING and MONMOUTH JUNCITON, N.J. — Yabao Pharmceutical Co. and Salus Pharma recently announced a partnership through which the two will co-develop, manufacture and commercialize generics with a high technological barrier. 

 

Under the partnership, Yabao will own commercialization rights outside the U.S. on certain products developed by Salus Pharma, and Salus will have commercialization rights in the U.S. The companies did not disclose financial terms of the partnership.

 

“Yabao is excited to collaborate with Salus Pharma, a specialty pharmaceutical company engaged in the research and development of high technological barrier controlled release formulation,” Yabao president of research and development and head of international business Dr. Peng Wang said. “This transaction represents our first generic drug partnership with Salus within this year. This partnership further demonstrates that Yabao’s competitive R&D and manufacturing have expanded into developed markets.”